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Aim: In vitro growth and elementary body (EB) associated cytotoxicity of two Chlamydia trachomatis
strains belonging to serovars D and H and C muridarum were compared to identify difference(s) that
correlate with virulence variations between these strains in the mouse model of human female genital tract
infection, and phenotypic characteristics that could explain human epidemiological data on serovar
prevalence and levels of shedding during serovar D and H infection.
Methods: Replication cycle kinetics, inclusion characteristics, and EB associated cytotoxicity were assessed
in McCoy cell monolayers using culture, light microscopy, and lactate dehydrogenase release.
Results: Over 72 hours, more rapid production and release of inclusion forming units (ifu) allowed
C muridarum to initiate two replication rounds, resulting in 4–8 times more ifu/input unit of infection than
with serovars D and H. Although C muridarum EBs were significantly more cytotoxic to McCoy cell
monolayers than serovar D at moderate and high multiplicity of infection ratios (MOI), serovar H EBs were
significantly more cytotoxic than C muridarum, even at the lowest MOI tested.
Conclusions: These phenotypic differences are consistent with the more invasive course and severe
pathological outcome of infection in mice infected with C muridarum, providing an objective basis for
questioning the appropriateness of C muridarum as a surrogate for the human biovar of C trachomatis in
the murine model of female genital tract infection. The differences seen between the human strains could
help explain human epidemiological data relating to differences in prevalence and level of shedding that
occurs during infection with oculogenital serovars D and H.
T
here are 19 distinct serotypes (serovars) of Chlamydia
trachomatis that infect humans, with serovars D, Da, E, F,
G, Ga, H, I, Ia, J, and K belonging to the group referred to
as oculogenital serovars, which are collectively the most
common sexually transmitted bacterial agents throughout
the world (chlamydia website (http://www.chlamydiae.
com)).1 There is little evidence to suggest differences in
virulence among oculogenital serovars, with a recent large
study concluding that the severity of disease was not
associated with a particular serovar or group of serovars.2
However, surveys of genital isolates from around the world
have consistently shown that certain serovars occur more
frequently than others, and that over time this pattern has
remained constant.3–9 Specifically, in large surveys in the USA
and Europe, serovars D and E account for approximately 50%
of genital C trachomatis isolates, whereas serovar H is isolated
from only 1–3% of culture confirmed infections. In addition,
differences in the level of shedding among serovars have
been noted in clinical specimens that roughly correlated with
serovar prevalence.10
‘‘Surveys of genital isolates from around the world have
consistently shown that certain serovars occur more
frequently than others, and that over time this pattern
has remained constant’’
In women, 70–80% of infections are asymptomatic and
repeated infection correlates with severe upper genital tract
pathology, which in decreasing order of occurrence includes
pelvic inflammatory disease, ectopic pregnancy, and tubal
infertility.11 The factors that contribute to a particular
outcome are unknown, but probably depend upon the
interplay between the host’s complex response to infection
and the equally complex, phenotypically variable, and
environmentally responsive biphasic intracellular develop-
mental cycle of chlamydia.
In attempts to understand the salient features of this
interplay, a great deal of work has been carried out using
slightly modified versions of a murine model of female
genital tract infection first described by Tuffrey and Taylor-
Robinson.12 Until recently, most of this work has been
conducted using C muridarum, the mouse pneumonitis
agent.13 However with the complete sequencing of
C muridarum and several chlamydial strains representing
human biovars of C trachomatis, studies are being conducted
that compare the more clinically relevant phenotypes that
might arise out of the variation seen at the genetic level.
Noteworthy in the present context are reported differences
between C muridarum and human oculogenital serovars in
sensitivity to interferon c14 15 and elementary body (EB)
associated cytotoxicity,16 with differences in interferon c
having a known effect on the course and outcome of female
genital tract infection in mice.17–19 We used this model to
determine whether the difference in prevalence among
oculogenital serovars might result from differences in
virulence and the observed significant differences in the
duration of infection among the various serovars that loosely
corresponded to the clinical prevalence of the serovars,
especially for the most and least prevalent serovars—D
and E versus H and I.20 In addition, the invasiveness and
level of bacterial shedding of the serovar D and H strains
Abbreviations: EB, elementary body; ifu, inclusion forming units; LDH,
lactate dehydrogenase; MOI, multiplicity of infection; SP, sucrose
phosphate transport medium
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demonstrated that serovar D was able to establish culture
confirmed infection of the uterine horns significantly more
frequently, in addition to shedding more during the acute
phase of infection. The factors that contribute to these
distinct phenotypes are unknown.
The purpose of our study was to analyse the in vitro growth
characteristics and EB associated cytotoxicity of the pre-
viously studied serovar D and H strains to identify differ-
ence(s) that might explain the observed variation in the
course of infection.20 Extrapolating the results of these
studies could provide insight into the factors that influence
serovar prevalence and levels of shedding that are seen in
human C trachomatis genital tract infection. Chlamydia
muridarum was included in these analyses both to confirm
the original observation relating to non-lipopolysaccharide
EB cytotoxicity and to identify phenotypic traits that might
explain the highly virulent and invasive nature of
C muridarum infection in the mouse compared with the less
virulent and invasive infection of human isolates in this
model of human disease.
MATERIAL AND METHODS
Chlamydia strains
Polymerase chain reaction based restriction fragment length
polymorphism serovar typed1 and mycoplasma free
C trachomatis strains belonging to serovars D, H, and L2 and
C muridarum was propagated and titrated in cycloheximide
treated McCoy cell monolayers using standard techniques.21
EBs were purified using density gradient centrifugation,22
and concentrated stock suspensions in sucrose phosphate
transport medium (SP) were frozen at 280 C˚.
Growth cycle analysis
Confluent McCoy cell monolayers (56 105 cells) in 24 well
tissue culture plates were inoculated with approximately 600
purified EBs. After centrifugation at 15006g for one hour at
37 C˚, monolayers were washed and incubated at 37 C˚ in fresh
medium. Immediately after and at eight, 24, 32, 48, 56, and
72 hours post-infection, culture supernatants and mono-
layers suspended in SP were collected separately and in
duplicate. Both types of specimens were sonicated and
immediately frozen at 280 C˚ until cultured for the presence
and enumeration of inclusion forming units (ifu) in McCoy
cell monolayers using iodine. A companion plate was used to
verify the actual input inoculum and to observe the kinetics
and microscopic appearance of iodine staining inclusions
throughout a 96 hour incubation period.
EB associated cytotoxin analysis
EB associated cytotoxicity was assessed in confluent McCoy
cell monolayers using two approaches: (1) visual evaluation
of the cytopathic effect with light microscopy; and (2)
measurement of changes in host cell membrane integrity
using a lactate dehydrogenase (LDH) release assay (cytotoxi-
city detection kit; Roche, Indianapolis, Indiana, USA). As a
control for possible cytopathic and membrane perturbing
effects resulting from particulate burden and chlamydial
lipopolysaccharide, a strain of C trachomatis L2 was included
in our analysis.16 McCoy cells were grown overnight in 48
well tissue culture plates (2.26 105 cells/well), and imme-
diately before use the culture medium was replaced with
serum free medium supplemented with 1% bovine serum
albumin and containing rifampin (10 mg/ml) and doxycycline
(5 mg/ml), to eliminate whole serum LDH activity and to
prevent bacterial metabolism during inoculation.16 Purified
EBs were diluted in SP and inoculated in duplicate on to
McCoy cell monolayers at multiplicity of infection (MOI)
ratios of 100 : 1, 25 : 1, 6.25 : 1, and 1.5 : 1. After centrifu-
gation at 15006g for one hour at 37 C˚, the supernatants
were collected, and the monolayers were washed and
incubated at 37 C˚ in antibiotic containing serum free bovine
serum albumin supplemented medium. Monolayers were
inspected using standard light microscopy and subjectively
scored for cytopathic effect immediately after inoculation,
and when aliquots of culture medium were collected in
duplicate at one, two, four, and six hours post-inoculation for
the LDH assay, performed according to the manufacturer’s
instructions.
RESULTS
Growth cycle analysis
Figure 1 shows the 72 hour replication and release kinetics
assessed under standard culture conditions. During this
period, C muridarum produced significantly more infectious
units in the first 24 hours than were produced during the
entire period for serovars D and H, and appeared to undergo
two rounds of replication, as indicated by the decrease in the
number of ifu isolated from monolayers between two peaks
at 32 and 72 hours. In addition, C muridarum infected cells
released ifu sooner—24 versus 48 hours—and in four to 10
times greater numbers than serovar D. In contrast, shedding
of serovar H was first seen at 32 hours and, when adjusted for
input, was both more sustained and equivalent to or greater
in magnitude than the numbers of ifu released from
C muridarum infected cells, resulting in the continued
reduction in monolayer associated ifu and a coincidental
increase in ifu recovered in the medium between 48 and 72
hours.
Microscopic observation of the iodine stained monolayers
revealed C muridarum inclusions by 24 hours, uniformly
increasing in size between 24 and 48 hours, followed
thereafter by a decrease in the number of large inclusions
and the appearance of an increasing number of small iodine
staining inclusions, often in clusters. This resulted in a
biphasic pattern of iodine staining inclusions (fig 2), with an
initial maximum of 885 at 32 hours, which was used as the
assigned value of the input inoculum, and a second peak of
860 at 72 hours, with both peaks corresponding to high
points of ifu recovery from the infected monolayer (fig 1).
In contrast, inclusion development was similar for serovars
D and H during the first 48 hours, with small iodine staining
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Figure 1 In vitro replication and release of Chlamydia trachomatis
serovars D and H and C muridarum.
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inclusions being first visible at 32 hours, followed by a
relatively uniform increase in size up to 48 hours. However,
beginning at 48 hours and continuing throughout the
incubation period, serovar H infected monolayers contained
inclusions that had apparently lost inclusion membrane
integrity, and appeared as more diffuse, smudge-like inclu-
sions within the cytoplasm of the cell.
The appearance of these distorted inclusions coincided
with a decrease in the number of inclusions in the monolayer
(fig 2) and an increase in ifu detected in the medium (fig 1).
The maximum number of iodine staining inclusions for
serovar D was seen at 56 hours (610) and for serovar H at 48
hours post inoculation (460). Between 48 and 96 hours of
incubation, iodine staining inclusions for serovar H decreased
to 41% of maximum at 56 hours to 8.6 % at 96 hours; over the
same period, serovar D dropped to 78% of maximum at 72
hours to 41% at 96 hours post-inoculation.
The net effect of these different replication and release
phenotypes was the production of a significantly greater
number of progeny/unit input for C muridarum (950 : 1)
compared with serovars D (235 : 1) and H (120 : 1).
EB associated cytotoxin analysis
Two methods were used to assess host cell cytotoxicity
associated with purified EBs—direct microscopic assessment
of the cytopathic effect and LDH release. Over time and in a
dose dependent manner, McCoy cells inoculated with EBs of
C muridarum or either oculogenital serovar showed signs of
toxicity, beginning with membrane perturbations at cell
junctions, visible as early as one hour, and proceeding to
varying levels of apparent lysis within two to four hours.
Although C muridarum EBs were significantly more
cytotoxic to McCoy cell monolayers at moderate (25 : 1)
and high (100 : 1) MOI ratios compared with serovar D,
serovar H EBs were significantly more cytotoxic than
C muridarum EBs, with an effect seen at the lowest MOI
(1.5 : 1) tested, both microscopically (table 1) and in the
more objective LDH release assay (table 2).
DISCUSSION
In an earlier study, we demonstrated a significant difference
in virulence characteristics among strains representing seven
oculogenital serovars of C trachomatis in the murine model of
female genital tract infection.20 In a comparison of the most
(serovar D) and least (serovar H) virulent strains in this
collection, the serovar D strain established a longer and more
invasive infection, which was characterised by more shed-
ding during the acute phase of infection. These findings
suggested that the differences in the prevalence and shedding
among serovars observed in humans might be related to
differences in the ability to establish more or less durable
infection, which may contribute to differences in genital tract
invasiveness.
In our in vitro study, we assessed the growth character-
istics and EB associated cytotoxicity of the serovar D and H
strains previously characterised in the mouse, and showed
that serovar H EBs were cytotoxic at an MOI of approxi-
mately 1 EB/McCoy cell, whereas a comparable level of
cytotoxicity was seen at an MOI of 25 for the serovar D strain.
This phenotypic difference, together with the possibly linked
differences in replication and release kinetics, might help
explain the differences in both the course of infection
between these strains in the mouse, and the incidence and
level of shedding between serovars D and H in human genital
tract infections.10
Based on the expression data presented in the original
description,16 it can be hypothesised that the cytotoxin plays a
role throughout the course of infection. It is possible that the
more cytotoxic serovar H EBs might cause the death of some
host cells upon contact, explaining the larger infectious dose
required to establish infection in mice. During the replication
cycle, newly produced cytotoxin could alter the integrity of
both the inclusion and cytoplasmic membranes, causing
earlier disruption of the replication cycle and premature lysis
of infected cells. This would explain both the earlier and
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Figure 2 Kinetics of iodine staining inclusion development in McCoy
cells.
Table 1 Direct microscopic assessment of the cytopathic effect of chlamydia EBs on McCoy cell monolayers
Time after inoculation
(hours)
Level of visual cytotoxicity seen in McCoy cell monolayers after infection with chlamydia EBs at the indicated MOI*
Chlamydia muridarum Serovar D Serovar H Serovar L2
1.5 6.25 25 100 1.5 6.25 25 100 1.5 6.25 25 100 1.5 6.25 25 100
0 – – – 1 – – – 1 – – 1 2 – – – –
1 – – 1 2 – – 1 2 – 2 3 3 – – – –
2 – – 2 3 – – 2 2 1 3 3 4 – – – 1
4 – – 3 4 – – 2 3 2 3 4 4 – – – 1
6 – 1 3 4 – – 2 3 2 3 4 4 – – – 1
*Confluent McCoy cell monolayers were infected at MOIs of 1.5–100 and incubated at 37 C˚ in the presence of 10 mg/ml of rifampicin and 5 mg/ml of
doxycycline. The cytopathic effect was evaluated immediately after infection and at 1, 2, 4, and 6 hours post-infection, and was subjectively scored from negative
(–) to positive using a scale of 1 to 4, on the basis of the degree of loss in cell membrane integrity and apparent lysis compared with non-infected control
monolayers: 4, complete disruption with apparent lysis; 3, significant perturbation, with some level of apparent lysis; 2, significant membrane perturbation; 1,
slight but noticeable affect; –, same as control. Immediately after centrifugation, all monolayers inoculated at MOIs of 25 and 100 contained cells with multiple
intracellular vacuoles that were not seen at lower MOIs or in uninoculated monolayers. No difference in degree of vaculation was seen among the strains and no
cytopathic score was assigned to this observation because over the course of the experiment these vacuoles disappeared in surviving cells, being completely absent
in L2 inoculated cells by 4 hours.
EB, elementary body; MOI, multiplicity of infection.
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larger number of ifu released into the medium, the
appearance of smudge cells, the disappearance of more cells
with intact inclusions from the monolayer, and the produc-
tion of less total ifu during the course of in vitro infection
with serovar H. During genital tract infection, this would
result in the release of less ifu, as previously described in both
mice20 and humans.10 Ultimately, less shedding would reduce
the number of ifu available to sustain infection, which might
contribute to a shorter and less invasive infection, as seen in
the mouse model, and a reduced level of transmission among
humans, which would explain the well documented differ-
ence in the prevalence of infection with these serovars in
human populations from around the world.3–9
‘‘The ability to produce large numbers of infectious units
rapidly probably contributes to the ability of C muridarum
to ascend the genital tract and ultimately deliver an
infectious challenge to the upper genital tract within the
first seven days of infection, which results in the severe
pathology seen during C muridarum infection’’
Relatively little use has been made of the murine model to
characterise human oculogenital serovars of C trachomatis,
with most investigators choosing to use C muridarum. The
historical basis for this selection, most recently expressed in a
review article by Morrison and Caldwell,23 rests almost solely
on the ability of C muridarum to cause severe upper genital
tract pathology and a high incidence of infertility after a
single infection with as few as 100 ifu. This is in contrast to
human isolates, including the serovar D and H strains used in
our study, which have a limited ability to ascend from the
lower genital tract with major pathological consequences
after infection, even with as many as 107 ifu.20 24–26 Originally,
this important difference in virulence was attributed to
adaptive evolutionary responses between C muridarum and its
natural host, the mouse. It was later suggested that the
relatively greater resistance of C muridarum to the infection
modifying effects of interferon c contributes to its virulent
phenotype. However, interferon c alone cannot explain either
the significantly later but equivalent magnitude of shedding
that occurs during the early course of infection in interferon c
knockout mice infected with serovar D compared with
C muridarum or the ability of exquisitely interferon c sensitive
oculogenital serovars14 to establish infection within the
genital tract of normal mice.20 Alternatively, our results
demonstrate an inherent difference between these biovars
that can better explain this difference. The ability of
C muridarum to produce and release infectious units at a rate
at least 2.5 times that of human oculogenital serovars, and
perhaps more importantly in a 24 hour time frame, certainly
has important consequences on the course and outcome of
infection, the effectiveness of innate immunity, and the type
and level of acquired immune responses made to infection.
This ability to produce large numbers of infectious units
rapidly probably contributes to the ability of C muridarum to
ascend the genital tract and ultimately deliver an infectious
challenge to the upper genital tract within the first seven
days of infection, which results in the severe pathology seen
during C muridarum infection.27 One can speculate that in the
process C muridarum is capable of avoiding the innate
immune system during each round of replication, being
ultimately confined and contained by the aggressive inflam-
matory and immune response that occurs either just before or
coincidental with the involvement of the entire genital tract,
which in this last instance results in infertility.28
Although compelling in its focus on the most severe
sequelae associated with infection, C muridarum infection of
the mouse female genital tract is not, in many of its features,
analogous to human infection with oculogenital serovars of
C trachomatis, particularly in the nature of the severe upper
genital tract pathology it is meant to mimic. This infrequent
and previously overestimated outcome associated with
infection29 is thought to be a chronic process associated with
either persistent or multiple infections, in which host
Table 2 Assessment of LDH release from McCoy cell monolayers after inoculation with chlamydia EBs
Time after inoculation
(hours)
% LDH release from McCoy cell monolayers after inoculation with chlamydia EBs at the indicated MOI*
Chlamydia muridarum Serovar D Serovar H Serovar L2
1.5 6.25 25 100 1.5 6.25 25 100 1.5 6.25 25 100 1.5 6.25 25 100
0 0 0 0 3 0 0 0 3 0 0 3 12 0 0 0 1
1 0 0 2 29 0 0.6 3 14 0.4 13 72 90 0 0 0 0.4
2 0 0.4 29 93 0 0.8 6 26 5 70 83 90 0.3 0 0.1 0.7
4 0 1 72 94 0 0.7 14 48 13 77 79 84 0.7 0.3 0 1
6 1 2 89 97 0.8 1 23 65 15 80 82 83 0.7 0.6 0.6 1
*Confluent McCoy cell monolayers were infected at MOIs of 1.5, 6.25, 25, and 100, and incubated at 37 C˚ in the presence of 10 mg/ml of rifampicin and 5 mg/
ml of doxycycline. LDH release was assayed in the supernatant immediately after inoculation and in aliquots taken at 1, 2, 4, and 6 hours post-inoculation. The per
cent release was calculated using the total cell LDH activity released during the complete lysis of uninoculated monolayers as 100%. Spontaneous release from
uninoculated monolayers was negligible at all time points.
EB, elementary body; LDH, lactate dehydrogenase; MOI, multiplicity of infection.
Take home messages
N Differences in elementary body associated cytotoxicity
between Chlamydia trachomatis serovars D and H are
linked with in vitro growth characteristics that can
explain both the shorter and less invasive course of
serovar H infection in the mouse female genital tract,
and more importantly the higher prevalence and
greater level of shedding that have been seen in
human infections with serovar D
N Differences seen between C muridarum and
C trachomatis serovars D and H, particularly the
much faster in vitro replication and release kinetics,
correspond to the more rapid and invasive course of
mouse genital tract infection with C muridarum
compared with human oculogenital serovars
N Taken together with previously published reports, these
findings provide an objective basis to question the
appropriateness of C muridarum as a model strain in
the murine model of human female genital tract
infection, and establish the model’s capacity to assess
the potential effects of phenotypic differences among
human isolates on the course and outcome of human
infection
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susceptibility factors play a role, and not the result of
inflammatory processes associated with a single acute disease
episode. In contrast, infection of the mouse with human
strains mimics in many ways both the course and outcome of
infection in most women—that is, an asymptomatic and self
limiting infection that only rarely results in severe upper
genital tract sequelae. The results presented in our study,
together with other reports describing differences in poten-
tially virulence determining phenotypes between C muridarum
and human isolates, again raise the issue of the appropriate-
ness of C muridarum as a model agent in the murine model of
female genital tract infection.30 The issue is made more
compelling given that the collection of phenotypes that
define C muridarum may not have a single counterpart in the
diverse collection of serovars that comprise the human
oculogenital biovar of C trachomatis. Systematic in vitro and
in vivo investigation of the phenotypic variation among
human disease causing strains could provide results with
translational value that will help direct the development of a
vaccine and/or other intervention strategies effective against
C trachomatis genital tract infections.
In conclusion, the results of our study provide a strain
specific phenotype based explanation for the profound
differences in the course and outcome of female genital tract
infection in mice infected with strains belonging to the
human oculogenital biovar of C trachomatis and C muridarum,
raising the issue of the appropriateness of using C muridarum
as a surrogate for C trachomatis in this model of human
disease. More importantly, the human epidemiological data
relating to differences in the prevalence and level of shedding
that occurs during infection with oculogenital serovars D and
H can be understood in the context of defined phenotypic
characteristics.
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